Vaccine-induced serum neutralizing activity against the B.1.351 variant is diminished, but effects on vaccine efficacy remain uncertain.
Concerns are growing that immune responses induced by natural infection or vaccines may be less effective against SARS-CoV-2 variants such as B.1.351 (the dominant lineage in South Africa). Now, investigators have evaluated the ability of serum from recipients of two doses of the BNT162b2 (Pfizer) vaccine or the mRNA-1273 (Moderna) vaccine to neutralize emerging SARS-CoV-2 variants in comparison with earlier viral lineages.
In one study, researchers measured BNT162b-provoked neutralizing antibody titers against USA-WA1/2020 (an early SARS-CoV-2 isolate), recombinant virus containing the globally dominant D614G substitution, and virus containing spike gene mutations from the B.1.351 lineage. The neutralizing titer against the B.1.351-spike vi…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)